VR 102
Alternative Names: Long acting estriol vaginal ring - Mithra Pharmaceuticals/VaRi Bioscience; Long acting estriol vaginal ring - VaRi Bioscience /Mithra CDMO; VR-102Latest Information Update: 31 Mar 2023
At a glance
- Originator Mithra Pharmaceuticals; VaRi Bioscience
- Class Anti-inflammatories
- Mechanism of Action Estrogen receptor agonists; Hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Atrophic vaginitis
Most Recent Events
- 02 Feb 2023 Mithra collaborates with VaRi Bioscience for the development of long-acting (3 months) estriol (E3)-based vaginal ring
- 02 Feb 2023 Phase II trial in Atrophic vaginitis in Germany (Vaginal, Ring)
- 28 Feb 2022 VaRi Bioscience files for patent protection with European Patent Office for innovative formulation concepts (VaRi Bioscience website, February 2023)